Neovascularization, Pathologic - 25 Studies Found
Completed |
: Effectiveness and Safety of Topical Ranibizumab for Treatment of Corneal Neovascularization (NV) : Corneal Neovascularization : 2008-05-19 : Drug: Ranibizumab 10 Patients will receive treatment (Ranibizumab) |
Recruiting |
: Special Drug Use Investigation of EYLEA for Myopic Choroidal Neovascularization : Choroidal Neovascularization : 2014-10-06 : Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) Administration by intravitreal injection |
Completed |
: Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization : Corneal Neovascularization : 2007-08-06 : Drug: Bevacizumab (Avastin) Bevacizumab 10mg/mL 1 drop BID x 3 weeks |
Recruiting |
: Dosing Strategy of Intravitreal Ranibizumab for Pathological Myopia Choroidal Neovascularization : Choroidal Neovascularization : 2016-08-21 : Drug: 0.5mg intravitreal ranibizumab Patients received ranibizumab (0.5mg, Novartis AG, Basel, Switzerla |
Recruiting |
: Intravitreal Conbercept for Idiopathic Choroidal Neovascularization : Idiopathic Choroidal Neovascularization : 2016-07-27 : Drug: conbercept 0.05ml conbercept Other Name: conbe |
Recruiting |
: Ranibizumab for Myopic Neovascularization : Myopic Choroidal Neovascularization : 2010-11-20 : Drug: ranibizumab injection Ranibizumab intravitreal injection of 0,5 mg ( 0.05mL) |
Recruiting |
: Efficacy of Aflibercept (Eylea®) on Choroidal Neovascularization (Type 3) : Type 3 Choroidal Neovascularization : 2014-12-10 : Drug: Aflibercept |
Completed |
: Ranibizumab to Treat Choroidal Neovascularization (CNV) in Patients With Pseudoxanthoma Elasticum (PXE) : Choroidal Neovascularization : 2007-08-01 : Drug: Intravitreal injection ranibizumab Monthly intravitreal injection of 0.5mg ranibizumab in one eye |
Completed |
: Aflibercept Intravitreal Injection for Myopic Choroidal Neovascularization : Choroidal Retinal Neovascularization : 2013-12-31 : Drug: Aflibercept Injection Aflibercept intravitreal injection |
Completed |
: Ranibizumab for the Treatment of Choroidal Neovascularisation (CNV) Secondary to Pathological Myopia (PM): an Individualized Regimen : Choroidal Neovascularisation : 2009-12-21 : Drug: ranibizumab 0.5mg |